Protox Therapeutics Inc. Initiates Phase 2 Prostate Cancer Study

15 Jan 2008

·www.biospace.com

VANCOUVER, Jan. 15 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX), a leader in the development of targeted therapeutic proteins, today announced that the Company has received Institutional Review Board (IRB) approvals to proceed with its Phase 2a clinical trial evaluating PRX302 for the treatment of localized recurrent prostate cancer. Activities associated with patient screening have commenced and the Company expects to enroll the first patient in the first quarter of 2008.

Organizations

Sophiris Bio, Inc.

Indications

Prostatic CancerRecurrent Prostate Carcinoma

Targets

Drugs

Topsalysin

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.